抗Glucagon (9C1) Monoclonal抗体 | Anti-Glucagon (9C1) Monoclonal Antibody

• Bioss 社抗体製品の特長
• 価格表
• 使用例
• Background
• 製品情報

Bioss 社抗体製品の特長

• ウエスタンブロット、免疫組織化学（IHC-frozen、IHC-paraffin）、免疫蛍光（IF）、ELISAなどのアプリケーションに適した一次抗体がラインナップされています。
• 一次抗体はすべて、Protein AまたはProtein G精製されています。
• 幅広い研究分野に関連する抗体を取り揃えています。


※最新の適用、交差性情報の詳細は、下記製品情報項の「データシート」リンクをご参照ください。

目次に戻る

価格表

目次に戻る

使用例

Lane 1: HepG2; Lane 2: HT-29 lysate at 20 µg per lane, probed with bsm-51090M Glucagon (329CT36.10.10) Monoclonal Antibody at 1:1000 dilution and 4℃ overnight incubation, followed by secondary antibody incubation for 60min at room temperature.

目次に戻る

Background

Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

目次に戻る

製品情報

name	Glucagon (9C1) Monoclonal Antibody
datasheet	最新のデータシートはこちらをご確認ください
Conjugation	Unconjugated
Gene ID	2641
Swiss Prot	P01275
Source	This Glucagon antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 119-148 amino acids from human Glucagon.
Purification	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Synonyms	GLP1; GLP2; GRPP; Glucagon; GCG

目次に戻る